Free BCACP Clinical Literature Interpretation Questions and Answers — Questions and Answers
Question 1: A pharmacist reviews a randomized controlled trial comparing a new lipid-lowering agent to placebo. The primary endpoint was major adverse cardiovascular events (MACE). The event rate in the placebo group was 12% and in the new agent group was 8%. What is the number needed to treat (NNT) to prevent one MACE?
- 4
- 8
- 12
- 25 (Correct answer)
Correct answer: 25
The Number Needed to Treat (NNT) is the reciprocal of the Absolute Risk Reduction (ARR). First, calculate the ARR: ARR = (Event Rate in Control Group) - (Event Rate in Treatment Group) = 12% - 8% = 4% or 0.04. Then, calculate the NNT: NNT = 1 / ARR = 1 / 0.04 = 25. This means 25 patients need to be treated with the new agent to prevent one additional MACE compared to placebo.
Question 2: A clinical trial evaluates a new medication for stroke prevention in patients with atrial fibrillation. The results for the primary outcome of ischemic stroke are reported as a Hazard Ratio (HR) of 0.80 with a 95% Confidence Interval (CI) of 0.65 to 1.05. Which of the following is the most accurate interpretation of this finding?
- The new medication is superior to the comparator for stroke prevention.
- The new medication is inferior to the comparator for stroke prevention.
- The result is not statistically significant. (Correct answer)
- The p-value must be less than 0.05.
Correct answer: The result is not statistically significant.
For a ratio metric like a Hazard Ratio (HR), Relative Risk (RR), or Odds Ratio (OR), the null value (representing no difference between groups) is 1.0. A 95% Confidence Interval indicates a range where the true effect is likely to lie. Because this 95% CI (0.65 to 1.05) crosses 1.0, we cannot exclude the possibility of no difference. Therefore, the result is not statistically significant at the p<0.05 level.
Question 3: Researchers wish to determine if exposure to a certain workplace chemical is associated with the development of a rare form of cancer. They identify a group of individuals with the cancer (cases) and a similar group without the cancer (controls). They then look back in time, using work history records, to determine the rate of chemical exposure in each group. Which study design does this describe?
- Randomized Controlled Trial
- Prospective Cohort Study
- Case-Control Study (Correct answer)
- Cross-Sectional Study
Correct answer: Case-Control Study
This describes a case-control study. This design starts by identifying individuals with the outcome of interest (cases) and a comparable group without the outcome (controls). It then looks retrospectively to compare the frequency of exposure to a risk factor in both groups. A prospective cohort study would start with exposed and unexposed groups and follow them forward in time to see who develops the disease.
Question 4: A large, multicenter randomized controlled trial is analyzed using the intention-to-treat (ITT) principle. What is the primary advantage of using an ITT analysis?
- It provides the most accurate estimate of the drug's efficacy when taken perfectly as prescribed.
- It preserves the benefits of randomization and reflects a more realistic measure of treatment effectiveness. (Correct answer)
- It increases the statistical power by excluding non-adherent patients from the final analysis.
- It is the preferred method for non-inferiority trials to avoid bias towards the null.
Correct answer: It preserves the benefits of randomization and reflects a more realistic measure of treatment effectiveness.
The intention-to-treat (ITT) principle analyzes all participants in the group to which they were originally randomized, regardless of whether they received the treatment or adhered to the protocol. The primary advantage is that it maintains the prognostic balance created by the initial randomization, preventing biases that can occur when patients drop out or are non-adherent. This approach provides a more pragmatic and real-world estimate of the treatment's effectiveness.
Question 5: A clinical trial for a new heart failure medication reports a statistically significant reduction in its primary composite endpoint of 'cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.' An analysis of the individual components reveals the benefit was driven almost exclusively by a reduction in urgent heart failure visits, with no significant difference in CV death or hospitalizations. What is the most appropriate clinical interpretation?
- The drug is proven effective at reducing mortality and hospitalizations in patients with heart failure.
- The composite endpoint is invalid and the study results should be disregarded entirely.
- The benefit of the drug is primarily related to reducing less severe events like urgent heart failure visits. (Correct answer)
- The drug is likely to show a mortality benefit if the trial is extended for a longer duration.
Correct answer: The benefit of the drug is primarily related to reducing less severe events like urgent heart failure visits.
When evaluating a composite endpoint, it is crucial to examine the individual components to understand the true effect of the intervention. A significant result for the composite does not automatically apply to all its components. In this case, the benefit was driven by the softest, least severe endpoint, so the most accurate interpretation is that the drug's main effect is on reducing urgent HF visits, not necessarily on the more severe outcomes of hospitalization or death.
Question 6: In a clinical study, researchers conclude that a new therapy is superior to placebo (p=0.04). In reality, however, no true difference exists between the therapy and placebo. What type of error has occurred?
- Type II error
- Confounding bias
- Selection bias
- Type I error (Correct answer)
Correct answer: Type I error
A Type I error occurs when the null hypothesis (which states there is no difference) is incorrectly rejected. In this case, the researchers concluded there was a difference (rejected the null hypothesis) when one did not actually exist. This is also known as a 'false positive.' The probability of making a Type I error is represented by alpha (α), which is the p-value threshold for statistical significance (commonly set at 0.05).
Free BCACP Clinical Literature Interpretation Questions and Answers
A pharmacist reviews a randomized controlled trial comparing a new lipid-lowering agent to placebo.
The primary endpoint was major adverse cardiovascular events (MACE).
The event rate in the placebo group was 12% and in the new agent group was 8%.
What is the number needed to treat (NNT) to prevent one MACE?